Deep learning in cancer diagnosis, prognosis and treatment selection

KA Tran, O Kondrashova, A Bradley, ED Williams… - Genome Medicine, 2021 - Springer
Deep learning is a subdiscipline of artificial intelligence that uses a machine learning
technique called artificial neural networks to extract patterns and make predictions from …

Artificial intelligence-assisted diagnostic cytology and genomic testing for hematologic disorders

L Gedefaw, CF Liu, RKL Ip, HF Tse, MHY Yeung… - Cells, 2023 - mdpi.com
Artificial intelligence (AI) is a rapidly evolving field of computer science that involves the
development of computational programs that can mimic human intelligence. In particular …

Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary

I Moon, J LoPiccolo, SC Baca, LM Sholl, KL Kehl… - Nature Medicine, 2023 - nature.com
Cancer of unknown primary (CUP) is a type of cancer that cannot be traced back to its
primary site and accounts for 3–5% of all cancers. Established targeted therapies are …

AI-based pathology predicts origins for cancers of unknown primary

MY Lu, TY Chen, DFK Williamson, M Zhao, M Shady… - Nature, 2021 - nature.com
Cancer of unknown primary (CUP) origin is an enigmatic group of diagnoses in which the
primary anatomical site of tumour origin cannot be determined,. This poses a considerable …

A cross-cohort computational framework to trace tumor tissue-of-origin based on RNA sequencing

B He, H Sun, M Bao, H Li, J He, G Tian, B Wang - Scientific reports, 2023 - nature.com
Carcinoma of unknown primary (CUP) is a type of metastatic cancer with tissue-of-origin
(TOO) unidentifiable by traditional methods. CUP patients typically have poor prognosis but …

[HTML][HTML] Artificial intelligence in pharmaceutical sciences

M Lu, J Yin, Q Zhu, G Lin, M Mou, F Liu, Z Pan, N You… - Engineering, 2023 - Elsevier
Drug discovery and development affects various aspects of human health and dramatically
impacts the pharmaceutical market. However, investments in a new drug often go …

Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity

L Möhrmann, M Werner, M Oleś, A Mock… - Nature …, 2022 - nature.com
The benefit of molecularly-informed therapies in cancer of unknown primary (CUP) is
unclear. Here, we use comprehensive molecular characterization by whole genome/exome …

DNA methylation profiling to determine the primary sites of metastatic cancers using formalin-fixed paraffin-embedded tissues

S Zhang, S He, X Zhu, Y Wang, Q Xie, X Song… - Nature …, 2023 - nature.com
Identifying the primary site of metastatic cancer is critical to guiding the subsequent
treatment. Approximately 3–9% of metastatic patients are diagnosed with cancer of unknown …

Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features

L Nguyen, A Van Hoeck, E Cuppen - Nature communications, 2022 - nature.com
Cancers of unknown primary (CUP) origin account for∼ 3% of all cancer diagnoses,
whereby the tumor tissue of origin (TOO) cannot be determined. Using a uniformly …

Precision cancer medicine: Concepts, current practice, and future developments

A Edsjö, L Holmquist, B Geoerger… - Journal of Internal …, 2023 - Wiley Online Library
Precision cancer medicine is a multidisciplinary team effort that requires involvement and
commitment of many stakeholders including the society at large. Building on the success of …